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Development of
Ruthenium Drugs as
Anticancer Agents
CHEMISTRY THESIS
DANIEL BOY

Introduction:
Finding the cure for cancer is a major area of focus in today’s medicinal world. Statistics
stated in 2013 that 1 in 4 deaths in the United States can be attributed to cancer. 1 The matter of
curing cancer is highly complex. Practically, it is difficult to create a compound that will kill
diseased tissues without affecting healthy tissues. 2 In general cancerous cells are analogous
to healthy tissues; they simply have upregulated metabolic function leading to uncontrolled
growth. This does lead to differences that can be targeted but finding these differences and
creating therapeutics for these purposes requires a great deal of research. When researching new
drugs, it is important to create experiments that emulate biological conditions. Tumors are not
easy to replicate in a lab setting.3 This leads researchers to not only test viability of new drugs on
diseased cells, but also to critically analyze the methods by which testing occurs. It is important
to utilize in vitro method that bridges the gap between the lab and the clinical setting.
One drug that has been developed and used affectively for the treatment of cancer is
Cisplatin. This medication is a platinum-based compound that readily accepts the unpaired
electrons of sulfur and nitrogen containing compounds to form dative bonds. This allows the
platinum to bind with amino acids cysteine and methionine as well as many of the nitrogen bases
of nucleotides deforming nuclear DNA.4 The damaging of the DNA initiates apoptosis.5
Apoptosis is the desired method by which cancerous tissue is removed, because it is a controlled
method of cell death that causes little inflammation. Alternately, necrosis, a method of cell death
leading to inflammation and the damage of adjacent cells, is undesirable. 6,7 Cisplatin is injected
systematically into a patient’s circulatory system, and has been in use since FDA approval in
1978.8 It has been considered an “essential medicine” by the World Health Organization. 8

The mechanism by which Cisplatin affects DNA begins when the two chlorine ligands
are hydrolyzed, replaced by water molecules that donate a lone pair from the oxygen to the metal
center. Plasma has a high water-content so it is possible that hydrolysis will occur prior to
reaching diseased tissue. While this is the case, the chloride ion concentration is high in the
blood when compared to the inside of a cell (100µM versus between 4 and 12µM). This
difference allows the Cisplatin to maintain its integrity well enough in the blood to reach and act
within cells.5 With this in mind, researchers often seek to create drugs with analogous
mechanisms to Cisplatin’s.
Although Cisplatin has been highly beneficial for treating a wide range of cancers, it has
drawbacks that require discussion. A report by Hazlitt et. al indicates that this drug causes an
incidence of hearing loss for 63% of patients. The extent of hearing loss varies between
individuals. Cisplatin reacts within auditory cells causing apoptosis and the generation of
reactive oxygen species (ROS), a decrease in antioxidant enzymes, and an increase in
proinflammatory cytokines.8 Resistance within center cancer types is another issue that
diminishes the efficacy of Cisplatin’s use. Lung carcinoma tumor A549/CDDP is an example of
a known resistant cell type.2 Currently, research is seeking the mechanism by which resistance
occurs, but none of the accessed literature indicated a causative conclusion. To this point only
hypotheses have been proposed. Researchers are currently unable to monitor all the reactions that
Cisplatin undergoes within the cell due to miniscule concentrations. One theory is that tumors
cells release excess amounts of glutathione (GSH). Cisplatin theoretically binds to the sulfur in
GSH prior to the being able reacting with DNA.4 The main reason for the side effects generally
associated with chemotherapy is Cisplatin’s inability to affect diseased tissue without damaging

healthy tissues. These include nausea and vomiting, loss of appetite, and hair loss. Since the
regular cells grow back and tumor cells do not, the side effects are tolerated. 7

Ruthenium Complexes: Targeting DNA
Current research is investigating ways to use ruthenium complexes as a substitute for
Cisplatin in hopes of finding medicines that are more specific to cancerous cells and that reduce
the side effects of chemotherapy. Due to the success of Cisplatin, many of these new drugs seek
to target the DNA of diseased tissues. Cisplatin has a square planar geometry5 while ruthenium
complexes have an octahedral geometry. This helps to increase the variability in the ligands
attached to the metal center allowing for higher specificity in targeting diseased tissues. 9 Many
ruthenium complexes are used in medicine currently,7 but the ruthenium complexes specified for
anticancer therapy have yet to become staples in treatment. It is desirable that some of them will
be applied to regular use in the near future. In this summary, the attractive aspects of ruthenium
complexes and the methods by which their efficacy is tested are investigated.
Within the precious metal therapeutics, ruthenium is the only metal that forms stable
complexes in oxidation states 2+ through 4+ under biological conditions. Ru(III) complexes are
less biologically active when compared to Ru(II) and Ru(IV) compounds. 7 Ruthenium is also in
the same d-block triad as iron and are able to bind to the protein transferrin that is found in a
higher amount on the outside of tumor cells as opposed to healthy cells. This diminishes the
chances of uptake of Ru complexes into healthy cells. Transferrin binds to the complex and
actively transports it into the cell. 10 Once there, the molecules are in an environment with low
oxygen levels. The hypoxic environment of diseased tissue leads to the reduction of Ru(III) to
Ru(II), the more reactive species. 6,11 Even if some of the Ru(III) compound were to be moved
into a healthy cell, the higher amount of oxygen would decrease the likelihood that reduction

would occur. As the reduced form, the complex theoretically will damage cancerous cell DNA
by causing cross-links that lead to apoptosis. One theory of the incidence of cross-linking is that
the octahedral geometry of ruthenium drugs leads to a “steric restriction.” This proposed
mechanism differs from the mechanism that Cisplatin employs to cause DNA deformation.
Research believe this may be why the drugs with Ru overcome the resistance some tumors show
towards the platinum drug.7
Another aspect of ruthenium complexes that makes them of interest is their similarity to
platinum’s ligand exchange.7 Ligand exchange determines biological activity of a complex.
Metal complexes are often activated when the ligands attached to the metal center react with
compounds with which they come in contact. If the ligands do not remain bound to the metal
center until they reach the desired location, the anticipated outcome will not result. 7,9 In the case
of anti-cancer agents, this result is stopping metastasis and/or causing cell death of diseased
tissue. Ruthenium complexes have shown to bind to DNA just as platinum based drugs do, but
many lack solubility which makes it difficult for them to be transported through the circulatory
system.6,7 Using the dialkyl sulfoxide derivative dimethylsulfoxide (DMSO) researchers were
able to create a soluble compound called NAMI-A. This compound binds to DNA much weaker
than Cisplatin12, and in vivo trials did not indicate DNA damage as the anticancer mechanism. 7
This was considered the most promising Ru(II) complex in 2001 7 due to the antimetastatic
capabilities.12 These antimetastatic capabilities are the reason it is called NAMI which means
“new anticancer metastasis inhibitor.”
Researchers have a litany of ligands to choose from that affect the characteristics of the
complex. Since anticancer agents are injected through into the blood stream, researchers must
create drugs that are able to dissolve in the blood without reacting. Patra, et. al describe a method

of incubation in human plasma that is utilized to test whether or not a substance degrade in an
environment that simulates blood flow.13 The substance in question is added along with an
equivalent volume of diazepam solution to blood plasma obtained commercially. This solution is
incubated with a gentle stirring of 300 rpm at 37℃ for a period 24 hours or more. The
researchers use this length of time because it far overshoots the time should remain in the blood
prior to reaching its desired location. After incubation Patra, et. al used a 2:1 ratio by volume of
methyl-tert-butyl ether/dichloromethane solution to stop any reaction that may be occurring. The
solvent was allowed to evaporate, and the solution was centrifuged so the organic layer could be
analyzed in HPLC-MS. A reverse phase column was used for the separation and ESI mode was
used for the mass spectrometry analysis. 13 Huang et. al used the same overall method as Patra et.
al only making slight modifications they saw necessary for the testing of their proposed
ruthenium anti-cancer therapeutics.2 Neither group explains explicitly how the decomposition of
their respective target substances are compared. They only stated that each maintain integrity
when incubated under the conditions previously described. It seems reasonable to assume that
the substance and diazepam solution is simply tested through the same analytical methods,
HPLC-MS, without incubation and compared to the results aforementioned. When viewing
results, diazepam is an internal standard with a distinct peak that will show up in the mass
spectrum. Since equivalent amounts of diazepam and the complex being tested are added, the
proportion of the peaks that result should be the same between the incubated and the nonincubated analytes.
Once the complex travels through the blood, it must be taken up by the cells. It is
indicated that cisplatin is taken up by cells mostly by passive diffusion. 5 Huang et. al sought the
mechanism by which the complex is taken up by the cell by incubating it in the presence of cell

uptake inhibitors. Eight different inhibitors of energy dependent and energy independent
entrance pathways were tested. By using Inductively Coupled Plasma-Mass Spectroscopy (ICPMS) the group found that [Ru(bpy)(phpy)(dppz)] + is not hindered by any uptake inhibitors that
block energy dependent pathways. Meaning it is most likely taken up by passive diffusion.
[Ru(bpy)(phpy)(dppz)]+ is only hindered by a high K+ concentration around the cytoplasm. This
high K+ concentration increases the membrane potential from around -70 to 0mV. Researchers
hypothesize that the positive charge on the complex makes it susceptible to changes in the cell
membrane potential.2
The localization of the drug in cells aids in creating the comprehensive dataset necessary
to begin formulating the mechanism of the therapeutic in question. Huang, et. al used ICP-MS
(Inductively coupled plasma mass spectrometry) to test the amount of different ruthenium
complexes that are able to reach the nucleus following incubation. ICP detects minute
concentrations as small as one part per 1015, the MS portion allows for quantification. The
machine nebulizes the analyte and moves it through plasma at a temperature high enough to
completely atomize the sample. This allows all the atoms present to be quantified individually. In
the case of precious metal cancer drugs, the metal center is the focus of this method. These
metals have a high mass relative to the other atoms present in the complex. Due to this element,
the issue of resolution in the spectra is diminished.
To test the difference of uptake into the nucleus versus the cytoplasm, a “nuclear and
cytoplasmic protein extraction kit.” This method requires that technicians start with a known
concentration of cells and counted following incubation in trypsin—EDTA solution. Next,
consecutive applications of centrifugation, collection of pellets, and resuspension in the various
solutions indicated by the kit are needed to separate the cytoplasmic and nuclear fractions

respectively. Once separated each fraction is tested in the ICP-MS separately and recorded.
Huang et. al indicated that 90% of the focal ruthenium complex was taken up to the nuclear
proteins after two hours (Figure 1).2

Figure 1. A representation of the change of concentration in the cytoplasm and the nucleus of
the three ruthenium complexes tested by Huang et. al over time. 2
Although accumulation in the nucleus is important for an anti-cancer drug, it does not
necessarily mean the drug will be cytotoxic. Huang, et. al tested cytotoxicity by 2D cancer cell
culture and 3D multicellular tumor spheroids (MCTSs). 2D analysis requires that a known
number of cells are cultured on a 96-well flat-bottomed multiwell plate. Huang et. al used 8
tumor cell lines and one human cell line. Since Cisplatin is the current drug widely used, it was
also used as an independent variable for the 2D analysis along with [Ru(bpy)2(dppz)]+ and
[Ru(bpy)(phpy)(dppz)]+.2 2D analysis is commonly used because many tests can be run can be
run at a time and results are reached quickly with high reproducibility.3 Incubation for this study
was 48 hours. For all eight cases of tumor cell lines tested, [Ru(bpy)(phpy)(dppz)]+ is more

cytotoxic than Cisplatin (Figure 2-2D). An interesting find by this group shows that
[Ru(bpy)(phpy)(dppz)]+ is even cytotoxic to a Cisplatin resistant line, A549/CDDP. Also,
[Ru(bpy)(phpy)(dppz)]+ is less cytotoxic to normal human cells. Cytotoxicity was represented as
IC50 in µM, which is 50 percent of the concentration needed to inhibit cell growth. In the case of
tumor cells, a lower number is desirable because this means the drug poignantly affects the
growth mechanism. For healthy cells, the ultimate goal is for a drug that will show as high of a
concentration as possible. Ultimately, a large disparity between the IC 50 of diseased tissue versus
normal tissue indicates that it is unlikely that the drug will affect both. IC 50 for
[Ru(bpy)(phpy)(dppz)]+ on healthy tissue is shown as 11.5µM, while the number is less than
4.3µM. This means that [Ru(bpy)(phpy)(dppz)]+ could be more selective than Cisplatin if used in
cancer therapy.2 While IC50 is the number used to represent the cytotoxicity of a therapeutic, it
has nothing to do with the actual dosage that would be used when a drug is utilized in a clinical
setting. The dosage is determined during the first stage of clinical trials. Cytotoxicity
measurements simply are one of the steps taken in vitro to determine whether or not further
testing of a drug should be pursued.
(2D)

Figure 2. ‘2D’ shows IC50 values for [Ru(bpy)(phpy)(dppz)]+, Cisplatin, and [Ru(bpy)2(dppz)]+
when incubated using 2D cytotoxic analysis. The focus is the comparison of the blue and the red
especially for culture A and E. A is normal cells while E is a Cisplatin resistant tumor cell type.

The rest from B-I are other cancerous tissue types. ‘a’ gives IC50 values for the 3 complexes
aforementioned by comparing the effects on a monolayer versus three sizes of MCTSs.2
The viability of 2D analysis is questioned because there is often a notable deviance
between in vitro and in vivo results for cytotoxicity.3,14 De Witt Hamer et. al tested how the
genomes of 2D cell lines and 3D MCTSs changed over a period of two weeks. In the majority of
the cases, 2D cultures showed low correlation after a two-week period. The samples that did not
show deviation after two weeks were tested at six and twelve weeks to find if changes may occur
at those points. Two of the cases in which a high correlation was maintained after two weeks
were further tested. Results showed that the genome of the primary cell cultures deviate further
from the parent tumor than the spheroid cultures when tested at 6 and 12 weeks. MCTSs show a
higher correlation to the parental tumor genome than primary cell cultures after twelve weeks.
The genetic change is significant, but the study does not claim that this variance is the reason that
differing results in a lab setting versus testing on small animals. There is simply evidence that the
biology of 2D cultures are less representative of the tumors. Correlation data is tested by using a
“genome-wide array comparative genomic hybridization (array CGH). 3
Huang, et. al included testing of MCTSs to give further information on the cytotoxicity of
their complexes (Figure 2-a). As previously mentioned, the genomic character of these spheroids
maintains a better correlation. Other aspects of these cultures that may also contribute to a higher
reflection of a true tumor are cellular heterogeneity, nutrient and oxygen gradients, and
proximity interactions of cell matrices. Creating MCTSs requires culturing a cell type followed
by dissociation into a single cancer cell isolate with a trypsin/EDTA solution. Once isolated the
cell is cultured to form the spheroid. Huang et. al grew their spheroids to 200, 300, and 400 µm
and found the cytotoxicity of [Ru(bpy)(phpy)(dppz)]+ as compared to Cisplatin. As the size of
the MCTSs increased, the cytotoxity decreased. In each case Ru(bpy)(phpy)(dppz)] + is more

cytotoxic when compared to Cisplatin. The ruthenium complex shows IC50 values that are
roughly twenty times lower at each spheroid size. 2 The development of 3D cytotoxic analysis
indicates the importance of researchers continuing to explore better methods of testing. As more
drugs fail to reach clinical use, researchers must take a step back and evaluate whether or not the
protocol of getting them there is viable. From the research done on MCTSs, an image of how this
is done is gained. The more realistic in vitro testing can be; the more confidence scientists can
have that the therapeutics they create will work.
One of the ways anticancer drugs can lead to apoptosis is by blocking transcription. To
do this, the drug must first be taken up the diseased tissue into the nucleus and bind to DNA.
Once bound to DNA, the complex can block RNA polymerase and/or transcription factors from
binding. Compound [Ru(bpy)(phpy)(dppz)] + showed the ability to block transcription and
specifically a transcription factor called, NF-κB. The in vitro uptake of [Ru(bpy)(phpy)(dppz)] +
into the nucleus is 90% after 2 hours of incubation making it an ideal compound to reduce the
formation of RNA and ultimately proteins through translation once bound. This is the
mechanism proposed by Huang et. al by which anticancer action occurs.2 Based on these positive
results, it is likely that researchers will continue to study the molecule discussed by Huang et. al.
Another way researchers begin to create an understanding of the mechanism is through
computational chemistry. Vargiu et. al used the computation method of Density Functional
Theory (DFT) to compute the energy levels of the hydrolysis products of NAMI-A to begin the
process of understanding its mechanism of action. 12 DFT is a method that is commonly applied
to syntheses. This group compared the energies of the complex when the metal in the plus three
and plus two oxidation states. As previously noted, ruthenium compounds are stable biologically
in both oxidation states and the difference in the oxidation can be beneficial for uptake into

cells.7 Vargiu et. al found that reduction was favored under biological conditions and even more
so in tumors due to the hypoxic environment of diseased tissue. 12,15 Also, the group found that
hydrolysis of DMSO competes when ruthenium is in the plus three state. While no conclusions
on how the hydrolysis affects the mechanism were made, the understanding of what hydrolysis
products are formed helps to move research toward specified study. 12 Researchers could use this
information Unfortunately, more recent literature explains the compound was not successful in
phase 2 of clinical trials.6 Therefore, the study to deduce the overall mechanism will not be
continued unless NAMI-A makes an unforeseen resurgence.

[Ru(bpy)(phpy)(dppz)]+
NAMI-A
Scheme 1. A display of the structures discussed in “Ruthenium Complexes: Targeting DNA”
section.

Photodynamic Therapy: Targeting the Mitochondria
A completely new angle has been sought since finding a ruthenium drug with an
analogous mechanism to Cisplatin has yet to be created. Photodynamic therapy (PDT) is a
method that requires a photosensitizer (PS) to be energized by light. Without light radiation, a
good photosensitizer will be inert in the body. The energy transfers to molecular oxygen species
that yields reactive oxygen species (ROS). 11,14,16 The ROS cause oxidative stress leading to tissue

damage8 to the immediate area in which the photosensitizers accumulate. Being that the
mitochondria is the powerhouse of the cell, it is an ideal location for the photosensitizers to
accumulate. Mitochondrion are the primary target because death that starts in these organelles
tend to lead to apoptosis rather than necrosis of the cell.14 Also, mitochondria targeting
ruthenium complexes have shown promising cytotoxic effects on Cisplatin resistant tumor
types9, making PDT agents a desirable replacement for Cisplatin if drugs can be applied
clinically.
Many PDT agents yield positive results when tested in vitro, but in vivo results are not as
promising. The need for a more realistic in vitro test of cytotoxicity to bridge the results2,3 leads
researchers of PDT agents to focus conclusions of cytotoxicity with the results gathered when
testing with multicellular spheroids (MCSs). Liu et. al explain that a MCS larger than 200µM
has a structure able to mimic the environment of tumor better than traditional monolayer
cultures.14 This is justifiable because the larger the spheroid, the more likely it will be for its
heterogeneity to be increased.
Another issue these compounds face is being irradiated once entering the tumor cells
coupled with the often hypoxic environment of tumors.14,15 The wavelengths of light used for
radiation can only penetrate so deep when it comes into contact with tissues. Generally, PS are
excited by light in the UV to the near infrared (NIR). NIR light is able to penetrate deeper than
light in the UV-Visible range but is still limited. Using UV light can also be damaging to the
cells by itself. Think about it. Skin cancer can occur from too much exposure to the UV rays of
the sun. Therefore, it is best to stay away from this type of light since side effects are bound to
arise.

There are two methods of irradiation within PDT that are used to excite the compounds.
Both involve a method called ‘one-photon activation’ uses light from UV-Visible range to excite
compounds most effectively. When the one-photon method uses light from the NIR, there is not
enough energy to activate complexes and create ROS. Fortunately, a method that irradiates
complexes with two photons simultaneously is effective in the NIR. The majority of original PS
were made within one-photon activation in mind. 17 Because of the desirable penetration of the
two-photon method, drugs that are receptive to this form of irradiation are highly sought
after.11,17
A paper by Liu et. al investigates four ruthenium complexes (Scheme 2) with 4,7diphenyl-1,10-phenanthroline (DIP) with the third ligand varying slightly for each. The third
ligand for RuL1 and RuL2 are available commercially. The difference between L1 and L2 in the
addition of an arene ring in place of the hydrogen. The L3 and L4 that were used could not be
acquired commercially and the group synthesized them prior to forming the complexes. L3
required a four-step synthesis and L4 needs three reactions to be complete. The yield of L3 with
the methods describe yielded 75% of the theoretical while L4 was 56%. Both are light yellow
precipitates when formed and purified.14 The ligands for L3 and L4 were created because RuL2
yields better PDT results than RuL1. The addition of triphenylphosphine (TPP) is added directly
to the non-DIP ligand in L2 to form L3 and indirectly via a flexible alkyl oxide chain attached to
L2 with an ether bond. The TPP addition is added to increase the solubility of the complexes and
in an attempt to add higher selectivity for mitochondria. 14 In some cases, increasing the solubility
negatively affects the cellular uptake of a therapeutic,18 but this is not the case for the TPP
ligands 3 and 4 used in the study by Liu et. al.14 The researchers noted that ES-MS, IR, 1HNMR,
and 31PNMR are the methods used to characterize the complexes. This paper describes the

experiments needed to test PDT agents in vitro. The group sought the two-photon absorption
(TPA) cross-section, the localization of the substances in cells, and made a comparison of ROS
production via the one-photon and two-photon methods
To find the wavelength at which excitation occurs, the TPA cross section (σ2),
spectroscopy is used. Equation 1 is dictated as the method for calculating the σ2 at different
wavelengths. ‘C’ is the concentration in M, ‘I’ is the integrated photoluminescent spectrum, and
‘n’ is the refractive index. The subscripts ‘S’ and ‘R’ represent whether the variable is sample or
reference respectively. Rhodimine B is the reference that Liu et. al used for their calculations.14
The method by which reference values for Rhodimine B are calculated is reported by Xu et. al.19
Zeng et. al follow a similar methodology in their study. The calculations by Zeng et. al are
performed at intervals of 10nm in the 2-photon range (760-900 nm14,17) and represented in
graphical for in Figure 3 with σ2 value on the y-axis and wavelength on the x-axis. A higher
value is desirable because it indicates that less radiation is needed to excite the drug. The highest
values for RuL1-L4 occur within the wavelengths 810-830.14 It is reasonable to find such
similarity for these four complexes due to the high degree of similarity in their ligands. Liu et. al
report the σ2 values in GM (1 GM = 1 x 10-50 cm s4 photon-1 molecule-1). For the complexes
tested, the GM values are 124-198, which is much higher than bioactive molecular probes, such
as; H2TPP. This higher number is inversely proportional to the intensity of the light needed to
cause excitation of the material. Therefore, the higher the σ2 is the lower the intensity of the light
used to irradiate the material needs to be. For RuL1-L4, L4 shows the highest GM value of 198
at 830nm.14 Performing this tests allows researchers to know what wavelengths to use once
testing of a PS on tumor cells commences. Also, it gives them an idea of which complexes
should need less light radiation to be activated.

𝜙 𝐶 𝐼 𝑛

Equation 1: 𝜎𝑆 = 𝜎𝑅 𝜙𝑅𝐶 𝑅𝐼 𝑆𝑛 𝑆

𝑆 𝑆 𝑅 𝑅

Figure 3. A graph showing the TPA cross-sections for the four ruthenium complexes tested by
Liu et. al at 10 nm intervals.
Liu et. al used an analogous method to Huang et. al to characterize the uptake location of
the ruthenium complexes into the cytoplasm and the nucleus. As previously stated, ICP-MS is
the analytical machine that is able to quantify the small concentrations and their distribution. In
this case the drug should accumulate in the cytoplasm, since that is the location of the
mitochondrion. RuL1-RuL4 all accumulate at concentrations above 90% of the incubated
amount into the cytoplasmic proteins after two hours.
The step that determines whether or not the drug is targeting the mitochondrion
specifically distinguishes the experimentation from other types of tracking methods. The
mitochondrion can be stained and viewed with one- and two-photon luminescent imaging with a
Laser Scanning Confocal microscope when incubated with MitoTracker Green (MTG). As the
name suggests, the mitochondrion show up as a bright green color on the image. The Ruthenium

complexes show up in a bright red color with the same imaging when excited by 458nm light.
These two images are then compared, and a correlation can be made. RuL4 shows a correlation
of 0.88 to the MTG image. This correlation factor then is multiplied by the percent concentration
of the ICP-MS results to yield how much of the substance localizes in the target location. ‘RuL3,
RuL2, RuL1, RuL4’ is the list of the results in increasing order for percent uptake into the
mitochondria given by Liu et. al when preforming this method. It is interesting to note that the
addition of TPP directly gave a less preferential accumulation to the mitochondria. It can be
concluded that the addition of the TPP does target mitochondrion more preferential when the
alkyl group spaces it from the non-DIP ligand.14

Figure 4. Images showing the Confocal Laser Microscope images of RuL4 and how the images
are merged to create the correlation of the complex localization in the mitochondria.
Since the creation of ROS is key to PDT agents inducing apoptosis, testing for the
formation of ROS is an important piece of research. This involves incubating the therapeutic in
question with a molecule like 2,7-dichlorodihydro-fluorescein diacetate (DCFH-DA) that is
hydrolyzed by esterase enzymes to DCFH. DCFH fluoresces when it comes in contact with
singlet oxygen (a ROS). This can be imaged with a confocal microscope with the intensity of

fluorescence directly correlating to the amount of singlet oxygen being formed. Each of the
compounds show significant fluorescence when irradiated by two-photon light.14 Therefore, ROS
are being created when the complexes are irradiated.
While ROS formation gives confidence that cell death will occur, cytotoxicity tests
remain an iteration in the research formula. Specifically, cytotoxicity in the dark must be
measured to ensure the complexes maintain the desired inert capability until irradiated. This
method is 2D and 3D analysis just as described by Huang et. al.2 In 2D monolayer analysis, IC50
values for RuL1-L4 have no cytotoxic effects in the dark with concentrations upwards of 100
µM. Once irradiated with J/cm2, RuL1-RuL3 show IC50 values near twelve, but RuL4
demonstrations highly positive results as it yields an IC50 of 3.5 µM. This result is expected since
RuL4 has the highest accumulation in the mitochondrion and high (σ22) value.14 Since RuL4
gave such positive results in the area of cytotoxicity and has such a large TPA cross section, the
group performed extra tests to see if the complex would remain cytotoxic when the amount of
radiation was diminished. This testing was performed using 2D analysis. For the main testing of
cytotoxicity, the light energy was 12 J/cm2. When the light dosage is diminished to 2 J/cm2 with
a concentration of 10µM, RuL4 kills 60% of cells after 2 hours. 50% are killed under the same
conditions when the light is reduced to 1.7 J/cm2. These results point to the positive effects of a
high TPA cross section coupled with high localization in the mitochondria. 14 While 3D analysis
is considered the best indicator of cytotoxicity, 2D analysis remains an important step for PDT
cancer research.14,20
In regard to 3D analysis, the MCTSs are important since few monolayers can be tested
with two-photon emission. As previously mentioned, the larger the diameter of the MCTS, the
better,14 and the increase theoretically gives a closer representation of a tumor in a clinical

setting. Also, spheroids above 600 µm can produce secondary necroses. 20 This is important
because it will give information as to which type of cell death a complex with induce. If necrosis
is caused by the cytotoxicity of a therapeutic in vitro, then researchers can critically consider
whether or not it is worth moving the drug on in testing. With this in mind, Liu et. al report using
an 800 µm spheroid14, doubling the size mentioned by Huang et. al.2 Testing of uptake into the
spheroid takes place in an analogous manner to the uptake into the cells of a monolayer. In the
case of MCTSs, the proposed drug is incubated for 8 hours and then viewed with fluorescence
microscopy. Each section of depth is recorded to show luminescence. Also, the creation of
singlet oxygen in the MCTSs is more prevalent near the outside of the culture. 14 This is
explained by the tendency of tumors and spheroids to have a hypoxic core. 14,15 RuL4 shows the
best luminescence for the ROS creation experiment. Finally, the cytotoxicity of RuL4 in the 3D
analysis is lowest for two-photon absorption at 1.9 µM compared to 9.6 µM for the one-photon
method.14 All in all, each of the four compounds14 show positive results following these in vitro
methods. The next step is to perform in vivo testing in hopes that the results continue and lead
these types of drugs into clincal testing. This paper does not include information on in vivo
methodology or data.

Scheme 2. Compounds reported by Liu et. al.14
Zeng et. al used four polypyridyl compounds (Scheme 3) with octupolar organization
with high chemical and photo stability.9 These compounds are quite similar to those used by Liu
et. al in that they are polypyridyl compounds. Polypyridyls are able to stabilize electrons in the
excited state which is the why they are often used in PDT. Zeng’s compounds main difference is
that they begin to include fluorine substituents that increase lipophilicity. This group focused on
seeing the uptake of their complexes into different types of cancers cells rather than the normal
HeLa cells used for this portion of testing by most other groups.2,14 There is not a substantial
difference for the uptake of the 4 ruthenium complexes into the 3 cacncerous tissues. The
important things to note from this study about uptake is that Zeng 4 gave the most positive
results. This compound is the most lipophilic, which indicates that lipophilicity and the uptake
are directly correlated.9 No indication of the reason for the correlation is given. Next, the group
also tested uptake into normal cells. For all four ruthenium compounds, the uptake into normal
cells is noticeably less. This shows some type of preference for tumor cells is can be concluded.
Since these compounds are PDT agents, it does not seem that this should be as important. It

seems that this is included because in clinical settings it may be difficult to focus light only onto
a tumor. There is usually healthy cell surrounding a tumor. If there is not compound in a healthy
cell, then the possibility of any negative effect to healthy tissue is diminished. Finally, the uptake
of cisplatin was compared. This was compared because a cisplatin resistance strain was used for
the research. This is important because the results show that the ruthenium complexes are able to
localize in a tumor type that cisplatin’s uptake is seriously diminished for. This results shows that
these complexes could be replacements for cisplatin resistant cancers.
Zeng et. al also focuses on the Thioredoxin system as a target for its compounds. This
system is studied because it includes thioredoxin reductase (TrxR) which activates Trx. Trx
seeks ROS helping to keep them from causing apoptosis. Also, Trx is involved in protein-protein
interactions that regulate multiple cellular functions. Multiple cancers upregulate TrxR which
makes it a possible drug target.9,21 Also, its function in reducing ROS allows it to play a role in
the resistance of Cisplatin. The tumor lines that are resistant commonly have a high TrxR amount
or upregulate the production of the compound. When the upregulation of TrxR occurs, the
resistance is considered “acquired” resistance. 21 Zeng et. al tested the effect of their most
promising probe on TrxR expression. The results show that Zeng’s fourth complex (Zeng 4)
reduces the expression of TrxR and its activity by 45% which leads to the increase of ROS.
Ultimately, this causes cell death. The ROS production is monitored with a confocal microscope,
once again, after incubation with DCFH-DA.9,14 This means the inhibition of TrxR plays a role
in Zeng 4’s anti-cancer mechansim.

Scheme 3. Ruthenium complexes discussed by Zeng et. al.9

Conclusion:
Overall, I found it difficult to find multiple further articles on the ruthenium complexes
{[Ru(bpy)(phpy)(dppz)]+}2 and PDT agent RuL4.14 I believe these two complexes show the
capability for further investigation of research. Furthering research will create clarity in the
conclusions and will provide more information about mechanisms of action. Many of these
articles indicate the importance of in vivo testing and the difficulties and variance that often arise
when moving to that step. Therefore, seeing the iterations for the complexes is imperative to the
process of instating new drugs into chemotherapy. Also, I would like to have seen in vivo based
articles solely for the purpose of gathering a better understanding into how those types of
experiments are formatted. It would be beneficial to compare how tumors are cultured and how
the small animals receive/integrate the tumors. Also, I wonder if cytotoxicity is measured and if
it is how this is performed. I assume that the process would be highly analogous.
I was encouraged on the one hand to see the multitude of ligands that are being studied
and have literature that can be assessed. It is interesting to see how varying structures do give

very different functions. I wish there was more information that explained the functionality of
the ligands rather than simply broad description. Most of the papers simply talk about the results
the new ligands have and how solubility/lipophilicity are the main factor that change the action
of the compounds.22 This reasoning was shallow to me because was not developed more by the
authors. I think this issue would diminish if the drugs showed more success and more research
focused on a specific drug continued. All the different structures show the lack of success that is
being had in this area of study. The in vitro results are easier to come by due to more
reproducibility. The way that spheroids are cultured does lead to some variance, but those
differences are exacerbated once testing moves on to live testing. Different DNA reacts to drugs
differently. It is similar to allergies. One person is able to eat gluten without issue while others
have extreme struggles with the protein. The further into the process of testing the drugs, the
more factors must be taken into account. I suppose if one takes the Thomas Edison approach,
then contentment can be maintained. All the failure in research brings scientists one step closer
to finding more beneficial ways to address cancer.
In the end, PDT agents do a good job of taking a novel approach to the problem. But, the
practicality of radiation to activate hinders the ability to use PDT for cancers in deep tissues. The
movement toward two-photo excitation aids in this process, but I do not know that PDT alone
with give a cure-all. It seems that cancer arises in too many forms to simply have one method
that will negate this type of disease. Also, I thought the focus on the Trx system and its part in
drug resistance is the kind of information that needs to be continually uncovered for better
therapeutic designs. The more we understand about how the ligands play vital roles in the
process of cancer treatment; the easier it will be to tune complexes with the correct ligands.
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